190 related articles for article (PubMed ID: 33122623)
21. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
22. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis.
Lian B; Yang D; Liu Y; Shi G; Li J; Yan X; Jin K; Liu X; Zhao J; Shang W; Zhang R
Cell Physiol Biochem; 2018; 49(6):2151-2162. PubMed ID: 30257253
[TBL] [Abstract][Full Text] [Related]
23. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
24. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH
Oncotarget; 2014 Jul; 5(14):5624-36. PubMed ID: 25015549
[TBL] [Abstract][Full Text] [Related]
26. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
[TBL] [Abstract][Full Text] [Related]
27. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Tecleab A; Zhang X; Sebti SM
J Biol Chem; 2014 Nov; 289(45):31296-309. PubMed ID: 25210032
[TBL] [Abstract][Full Text] [Related]
28. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Yue D; Sun X
Cancer Biol Ther; 2019; 20(3):284-294. PubMed ID: 30359552
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
30. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
31. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.
Gentry LR; Nishimura A; Cox AD; Martin TD; Tsygankov D; Nishida M; Elston TC; Der CJ
J Biol Chem; 2015 Sep; 290(37):22851-61. PubMed ID: 26216878
[TBL] [Abstract][Full Text] [Related]
32. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
33. Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.
Kim SL; Liu YC; Park YR; Seo SY; Kim SH; Kim IH; Lee SO; Lee ST; Kim DG; Kim SW
Int J Oncol; 2015 Mar; 46(3):1121-30. PubMed ID: 25502339
[TBL] [Abstract][Full Text] [Related]
34. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
[TBL] [Abstract][Full Text] [Related]
35. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
36. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
37. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
38. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
39. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
40. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Nakata S; Yoshida T; Shiraishi T; Horinaka M; Kouhara J; Wakada M; Sakai T
Mol Cancer Ther; 2006 Jul; 5(7):1827-35. PubMed ID: 16891469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
